IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.050
EU - Europa 380
AS - Asia 99
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 4
SA - Sud America 3
AF - Africa 2
Totale 1.556
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.019
IT - Italia 176
SE - Svezia 96
CN - Cina 51
GB - Regno Unito 45
CA - Canada 30
IN - India 28
EU - Europa 18
DE - Germania 14
RO - Romania 13
NL - Olanda 10
ES - Italia 7
IR - Iran 5
JP - Giappone 5
UA - Ucraina 5
FR - Francia 4
AU - Australia 3
CH - Svizzera 3
CL - Cile 2
DZ - Algeria 2
FI - Finlandia 2
HK - Hong Kong 2
MY - Malesia 2
PK - Pakistan 2
RU - Federazione Russa 2
BD - Bangladesh 1
BR - Brasile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
GT - Guatemala 1
KR - Corea 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 1.556
Salva come PNG Salva come JPEG
Città #
Chandler 234
Lawrence 107
Princeton 107
Wilmington 58
Catanzaro 45
London 41
Des Moines 40
Chicago 39
Ashburn 38
Beijing 32
Ottawa 28
Redwood City 13
Redmond 10
Pune 9
Cosenza 6
Horia 6
Leawood 6
Mountain View 6
Rome 6
Timisoara 6
Ahmedabad 5
Augusta 5
Reggio Calabria 5
Boardman 4
Hanover 4
Norwalk 4
Settingiano 4
Utrecht 4
Zhengzhou 4
Andover 3
Barcelona 3
Castrovillari 3
Cetraro 3
Ferrara 3
Hefei 3
Kumar 3
Masera 3
Milan 3
Naples 3
San Antonio 3
Santo Stefano di Rogliano 3
Shanghai 3
Apo 2
Bari 2
Bologna 2
Brescia 2
Brugnera 2
Ceglie Del Campo 2
Delhi 2
Fayetteville 2
Grottaglie 2
Hebei 2
Helsinki 2
Hong Kong 2
Karachi 2
Los Angeles 2
Madrid 2
Nanjing 2
New York 2
Paris 2
Portici 2
Saint-Fons 2
San Jose 2
Spezzano della Sila 2
Tlemcen 2
Ulm 2
Washington 2
Alexandria 1
Arnhem 1
Baotou 1
Buffalo 1
Candiolo 1
Casamassima 1
Catania 1
Chang-hua 1
Chemnitz 1
Chongqing 1
Clearwater 1
Decollatura 1
Fairfield 1
Guatemala City 1
Hyderabad 1
Kansas City 1
Kuala Lumpur 1
La Canada Flintridge 1
Lamezia Terme 1
Melbourne 1
Melito di Porto Salvo 1
Messina 1
Montréal 1
New Delhi 1
Novokuznetsk 1
Patna 1
Perth 1
Petaling Jaya 1
Roccella Jonica 1
San Mateo 1
Seattle 1
Selargius 1
Seoul 1
Totale 998
Salva come PNG Salva come JPEG
Nome #
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 51
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 48
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 42
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 39
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 39
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 35
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 34
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 34
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 33
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 32
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 30
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 29
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 27
Mir-221/222 are promising targets for innovative anticancer therapy 26
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 26
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 25
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 25
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 25
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 24
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 24
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 24
Daunorubicina liposomiale in ematologia 23
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 22
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 22
miR-22 suppresses DNA ligase III addiction in multiple myeloma 22
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 21
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 21
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 21
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 21
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 21
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 20
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 20
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 19
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 19
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 19
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 19
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 18
Mouse models of Multiple Myeloma: technologic platforms and perspectives 18
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 18
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 18
Mycosis fungoides and gastric t-cell lymphoma: A case report 17
MicroRNAs in multiple myeloma and related bone disease 17
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 16
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 15
Molecular Targets for the Treatment of Multiple Myeloma 15
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 14
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 14
Dendritic cells have the option to express IDO-mediated suppression or not 14
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 14
The non-coding RNA landscape of plasma cell dyscrasias 13
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 13
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 12
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 12
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 12
Immunologic microenvironment and personalized treatment in multiple myeloma 11
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 11
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 11
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 10
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 10
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 10
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 10
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 9
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 9
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 9
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 9
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 9
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 8
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 8
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 8
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 8
New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics 8
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 8
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 8
Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability 8
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 8
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety 8
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 8
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 8
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 7
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 7
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 7
Multiple myeloma-related bone disease: state-of-art and future treatments 7
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 7
Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential 7
miR-29b is involved in the differentiation of dendritic cells and osteoclasts from human monocytes 7
Phosphoproteomic analysis of miR-21 modulation in Th17 cells: Potential implications for multiple myeloma bone disease therapy 7
Plasmacytoid dendritic cells: a role after allogeneic stem cell transplantation? 6
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 6
Hedgehog pathway in myeloma pathobiology and as potential therapeutic target 6
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 6
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 6
Non Homologous End Joining, a Marker Of Genomic Instability Is Elevated In Multiple Myeloma: A New Prognostic Factor 6
Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines 6
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 5
Role of homologous end joining in multiple myeloma genetic instability and as a potential prognostic marker 5
Non Homologous End Joining As a New Prognostic Factor and Potential Target in Multiple Myeloma 5
Pharmacological activation of the alternative estrogen receptor GPER triggers anti-tumor activity in multiple myeloma and Waldenström macroglobulinemia cells 5
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 5
Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential 5
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 5
Totale 1.599
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.220
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.220
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020105 0 0 0 8 37 1 5 10 3 4 11 26
2020/2021200 4 1 8 10 23 12 7 20 36 35 39 5
2021/2022319 9 4 4 72 36 17 10 58 25 30 48 6
2022/2023737 225 37 34 46 71 55 4 50 106 39 53 17
2023/2024306 75 44 23 20 28 87 8 7 3 10 1 0
Totale 1.667